McLaughlin J K, Lipworth L, Chow W H, Blot W J
International Epidemiology Institute, Rockville, Maryland 20850, USA.
Kidney Int. 1998 Sep;54(3):679-86. doi: 10.1046/j.1523-1755.1998.00043.x.
Heavy use of analgesics, particularly over-the-counter (OTC) products, has long been associated with chronic renal failure. Most of the earlier reports implicated phenacetin-containing analgesics as the risk factor. Since the early 1980s. several case-control studies have reported associations between chronic renal failure and use of other forms of analgesics, including acetaminophen, aspirin, and other non-steroidal antiinflammatory drugs (NSAIDs). Findings from these studies, however. should be interpreted with caution because of a number of inherent limitations and potential biases in the study design and data collection procedures. These limitations include: failure to identify patients early enough in the natural history of their disease to collect reliable information on analgesic use at an etiologically relevant time period; selection bias due to incomplete identification of subjects or low response rates; selection of cases and controls from different population bases; failure to employ survey techniques to improve reliability of recall of analgesic use; failure to collect detailed information on analgesic use such as year started and ended and reasons for switching analgesics; lack of standardization in the definition of regular analgesic use; and failure to adjust for phenacetin use and other confounding factors when assessing associations with analgesics other than those containing phenacetin. It is our hope that this review of study design limitations will lead to improvements in future studies of chronic renal failure risk. Since use of analgesics is widespread and new OTC products are introduced frequently, the potential impact of these drugs on the development of chronic renal failure may be significant, thus warranting continued evaluation of these products for any renal toxicity.
长期大量使用镇痛药,尤其是非处方(OTC)产品,一直与慢性肾衰竭相关。早期的大多数报告认为含非那西丁的镇痛药是风险因素。自20世纪80年代初以来,几项病例对照研究报告了慢性肾衰竭与使用其他形式的镇痛药之间的关联,包括对乙酰氨基酚、阿司匹林和其他非甾体抗炎药(NSAIDs)。然而,由于研究设计和数据收集程序存在一些固有的局限性和潜在偏差,这些研究的结果应谨慎解读。这些局限性包括:在疾病自然史中未足够早地识别患者,以便在病因相关时间段收集关于镇痛药使用的可靠信息;由于受试者识别不完整或低应答率导致的选择偏倚;从不同人群基础中选择病例和对照;未采用调查技术来提高镇痛药使用回忆的可靠性;未收集关于镇痛药使用的详细信息,如开始和结束年份以及更换镇痛药的原因;常规镇痛药使用定义缺乏标准化;以及在评估与不含非那西丁的镇痛药的关联时未对非那西丁使用和其他混杂因素进行调整。我们希望对研究设计局限性的这一综述将导致未来慢性肾衰竭风险研究的改进。由于镇痛药的使用广泛且新的OTC产品频繁推出,这些药物对慢性肾衰竭发展的潜在影响可能很大,因此有必要持续评估这些产品的任何肾毒性。